This paper reviews recent contributions from a Bayesian-oriented perspective, after the ASA statement on p-values (2016). We classify proposals that (i) supplement the p-value; (ii) modify the p-value itself. In the first group, we review the Bayes factor, the False Positive risk, the rejection odds and the analysis of credibility from both Matthews’ and Held’s point of view. We also put forth and discuss a new index of credibility, about which we conduct a delimited simulation study. In the second group, we discuss Gannon’s modification of the p-value based on the Bayes factor and the second-generation p-value. The theory is illustrated with two case studies on pharmacotherapy in infectious diseases. Contemporary authors still refer to the p-value as a statistical indicator but have abandoned the perspective of evaluating p-values with fixed thresholds. Statistical societies worldwide should target new strategies to disseminate the debate on p-values in all applied fields of knowledge, as well as they may promote the use of different statistical procedures to supplement p-values.

Quatto, P., Ripamonti, E., Marasini, D. (2022). Beyond p < .05: a critical review of new Bayesian proposals for assessing the p-value. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 32(2), 308-329 [10.1080/10543406.2021.2009497].

Beyond p < .05: a critical review of new Bayesian proposals for assessing the p-value

Quatto, Piero
Primo
Membro del Collaboration Group
;
Ripamonti, Enrico
Secondo
Membro del Collaboration Group
;
Marasini, Donata
Ultimo
Membro del Collaboration Group
2022

Abstract

This paper reviews recent contributions from a Bayesian-oriented perspective, after the ASA statement on p-values (2016). We classify proposals that (i) supplement the p-value; (ii) modify the p-value itself. In the first group, we review the Bayes factor, the False Positive risk, the rejection odds and the analysis of credibility from both Matthews’ and Held’s point of view. We also put forth and discuss a new index of credibility, about which we conduct a delimited simulation study. In the second group, we discuss Gannon’s modification of the p-value based on the Bayes factor and the second-generation p-value. The theory is illustrated with two case studies on pharmacotherapy in infectious diseases. Contemporary authors still refer to the p-value as a statistical indicator but have abandoned the perspective of evaluating p-values with fixed thresholds. Statistical societies worldwide should target new strategies to disseminate the debate on p-values in all applied fields of knowledge, as well as they may promote the use of different statistical procedures to supplement p-values.
Articolo in rivista - Articolo scientifico
Scientifica
Analysis of credibility; Bayes factor; p-value; rejection odds; second-generation p-value;
English
Quatto, P., Ripamonti, E., Marasini, D. (2022). Beyond p < .05: a critical review of new Bayesian proposals for assessing the p-value. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 32(2), 308-329 [10.1080/10543406.2021.2009497].
Quatto, P; Ripamonti, E; Marasini, D
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/388768
Citazioni
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
Social impact